Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee; Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee.
Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee.
Biol Blood Marrow Transplant. 2017 Dec;23(12):2102-2109. doi: 10.1016/j.bbmt.2017.08.025. Epub 2017 Sep 1.
Abnormal pulmonary function is prevalent in survivors of allogeneic hematopoietic cell transplantation (HCT). Post-transplantation recovery of pulmonary function, and its effect on survival, in children are not known. This retrospective cohort study of 308 children followed for 10 years after HCT at a single institution included 2 groups of patients. Group 1 comprised 188 patients with 3 or more pulmonary function test (PFT) results, of which at least 1 was abnormal, and group 2 comprised 120 patients with 3 or more PFTs, all of which were normal. Pulmonary function normalized post-transplantation in 51 patients (27%) in group 1. Obstructive lung disease, restrictive lung disease, mixed lung disease, and normal pattern were seen in 43%, 25%, 5%, and 27% of patients, respectively, at a median of 5 years (range, 0.5 to 11.9 years) post-transplantation. Lung volumes recovered better than spirometric indices. Pulmonary complications were seen in 80 patients (43%) in group 1. Patients who recovered pulmonary function had better overall survival (P = .006), which did not differ significantly from that in patients in group 2 with normal lung function post-transplantation (P = .80). After adjusting for duration of follow-up, pulmonary complications (P = .01), and lower pretransplantation forced vital capacity z-scores (P = .01) were associated with poor recovery. T cell depletion (P < .001), lower pretransplantation forced expired volume in 1 second z-scores (P = .006), and chronic graft-versus-host disease (P < .001) increased the risk for pulmonary complications. Nonrecovery of lung function with pulmonary complications (P = .03), acute graft-versus-host disease (P = .004), and mechanical ventilation (P < .001) were risk factors for nonrelapse mortality. Normalization of pulmonary function is possible in long-term survivors of allogeneic HCT. Strategies to decrease the risk of pulmonary complications may improve outcomes.
异基因造血细胞移植(HCT)后患者常出现肺功能异常。但目前尚不清楚儿童患者移植后肺功能的恢复情况及其对生存的影响。这项回顾性队列研究纳入了在单一机构接受 HCT 治疗后随访 10 年的 308 例患儿,其中包括两组患者。第 1 组包括 188 例患者,这些患者至少有 3 次肺功能检查(PFT)结果异常,第 2 组包括 120 例患者,这些患者至少有 3 次 PFT 结果正常。第 1 组中,51 例(27%)患者在移植后肺功能恢复正常。在移植后 5 年(范围:0.5 至 11.9 年)中位数时,分别有 43%、25%、5%和 27%的患者出现阻塞性肺疾病、限制性肺疾病、混合性肺疾病和正常模式。与肺容积相比,肺功能的恢复更好。第 1 组中,80 例(43%)患者出现肺部并发症。肺功能恢复的患者总生存率更好(P=0.006),与移植后肺功能正常的第 2 组患者的生存率无显著差异(P=0.80)。在校正随访时间、肺部并发症(P=0.01)和较低的移植前用力肺活量 z 评分(P=0.01)后,肺功能恢复不良与较差的预后相关。T 细胞耗竭(P<0.001)、较低的移植前 1 秒用力呼气量 z 评分(P=0.006)和慢性移植物抗宿主病(P<0.001)增加了肺部并发症的风险。肺功能未恢复合并肺部并发症(P=0.03)、急性移植物抗宿主病(P=0.004)和机械通气(P<0.001)是无复发生存期死亡的危险因素。异基因 HCT 后长期生存者的肺功能可能恢复正常。降低肺部并发症风险的策略可能会改善预后。